Investor profile
Solas BioVentures
Life-science venture firm co-founded by physician-investor David Adair, who sits on the Arrivo BioVentures board. Fund I participated in Arrivo's 2016 launch financing and the Emerging Healthcare Fund in its 2023 Series B; the firm also invested in Basking Biosciences' 2023 round. Adair's prior boards include Aerial BioPharma (Morrisville, sold its lead asset to Jazz in 2014).
Directory portfolio
Companies connected here
2
- A
Arrivo BioVentures
Clinical-stage drug developer with two candidates: forvisirvat (SP-624), a SIRT6 activator in Phase 2b/3 for major depressive disorder, and RABI-767 for predicted severe acute pancreatitis.
Basking Biosciences
Clinical-stage biotech developing BB-031, a reversible RNA aptamer thrombolytic for acute ischemic stroke.
Portfolio coverage reflects public company-investor links tracked in this directory and may not represent the investor's full portfolio.